napharm glp 1 GLP-1 Weight Loss Treatment GLP-1 Therapy Weight Loss Medication
Description
The American Society of Anesthesiologists (ASA) recommends withholding these drugs before surgery, but definitive guidelines remain unclear
As 2025 gets underway, we take a look at what lies ahead for the highly dynamic market for effective anti-obesity medications (AOMs)
Glucagon-like peptide 1 receptor agonists and combination medications (GLP-1s) are shifting the treatment landscape for obesity
The Bottom Line GLP1 therapies are changing the game for T2D, and their influence is continuing to spread across the broader chronic disease landscape
A retrospective study counters some earlier findings linking GLP-1 receptor agonists with worsening retinopathy in patients with diabetes.
This analysis was part of the IMI-Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy (IMI-SOPHIA) project
